This centre uses ‘P4 Medicine’ to: prevent disease, predict disease progression, personalise treatment pathways, and empower patients to participate in their healthcare. Within the context of respiratory medicine, the centre will optimise treatment of common respiratory diseases by enabling precision medicine. Work done by this centre includes:
This centre is a member of the ABPI MRC stratified initiative in COPD, and has extensive infrastructure to deliver experimental medicine research, including:
This centre is world-leading in challenge models for asthma, and has extensive expertise in biomarker research and validation (part of the COPD biomarker qualification consortium subgroup working with the FDA on biomarkers in COPD).
Manchester was a founding member of the TRC, and hosted the Chief Investigator (CI) for the first Phase II study within the respiratory TRP (novel PDE4 inhibitor for COPD treatment, Chiesi Pharmaceuticals, Italy).
Led by Professor Dave Singh, other expertise includes:
COPD - Professor Jørgen Vestbo and Professor Geoff Parker
Cough - Professor Jaclyn Smith and Professor Ashley Woodcock
Asthma, including severe asthma - Dr Stephen Fowler, Dr Rob Niven, Professor Paul O’Byrne and Professor Angela Simpson